At the continuous dosing, Tregs were suppressed from day 10, and then NY-ESO-1-specific CD8+ T cells were induced at day 14 (online supplemental figure S1G), indicating that ZSTK474 treatment impairs Treg suppression, consequently inducing the activation of tumor antigen-specific CD8+ T cells. This evidence concerns the gene CD8A and neoplasm.